ArticleRevista do Instituto de Medicina Tropical de Sao Paulo2018
Evaluation of a new brand of immunochromatographic test for visceral leishmaniasis in Brazil made available from 2018.
Article in Revista do Instituto de Medicina Tropical de Sao Paulo, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Review
- Serology for visceral leishmaniasis: How trusty is the accuracy reported by the manufacturers?Revista da Sociedade Brasileira de Medicina Tropical · 2023Review
- Serosurvey of anti-Veterinary world · 2021Article
- Molecular Tracking of theFrontiers in cellular and infection microbiology · 2021Review
- Improved Performance of ELISA and Immunochromatographic Tests Using a New Chimeric A2-Based Protein for Human Visceral Leishmaniasis Diagnosis.Journal of immunology research · 2021Observational
- Laboratory Diagnosis of Cutaneous and Visceral Leishmaniasis: Current and Future Methods.Microorganisms · 2020Review
- Cost-effectiveness of serological tests for human visceral leishmaniasis in the Brazilian scenario.PLoS neglected tropical diseases · 2020Article
- Visceral Leishmaniasis diagnosis: a rapid test is a must at the hospital bedside.Clinics (Sao Paulo, Brazil) · 2020Article
- Evaluation of methods for detection of asymptomatic individuals infected with Leishmania infantum in the state of Piauí, Brazil.PLoS neglected tropical diseases · 2019Article
- A rapid diagnostic test for human Visceral Leishmaniasis using novelEmerging microbes & infections · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunochromatographic tests based on the recombinant antigen K39 represent a major advance in diagnosing visceral leishmaniasis (VL) in recent years. Some performance variations are expected and have occurred in the use of several commercial rapid tests, especially in different geographical settings. This is the first evaluation in the Americas of the test recently provided by the public health system in Brazil for the diagnostic of VL, the OnSite™ Leishmania IgG/IgM Combo. In this first clinical test evaluation, 113 VL-positive patient samples and 73 negative controls were tested and a sensitivity of 91.2% and specificity of 94.5% were observed. These results indicate the need for further analysis and comparisons with the performance of other available commercial tests in order to define the impact of this new test on the quality of VL diagnosis in Brazil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.